Efavirenz

Generic Name: Efavirenz

Brand Names: Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₉ClF_₃NO_₂

CAS Number: 154598-52-4

Unique Ingredient Identifier: JE6H2O27P8

Background: Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...

Indication: For use in combination treatment of HIV infection (AIDS)

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection

Not Applicable

Completed

Conditions: Acute HIV Infection

Interventions: Drug: Raltegravir
Drug: Efavirenz
Drug: Emtricitibine
Drug: Tenofovir disoproxil once daily
Drug: Tenofovir disoproxil twice daily

First Posted Date: 2008-08-14

Last Posted Date: 2016-05-30

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 18

Registration Number: NCT00734344

Locations: 🇺🇸
UAB 1917 Clinic, Birmingham, Alabama, United States

Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations

Phase 1

Completed

Conditions: HIV Infections
Malaria

Interventions: Drug: efavirenz
Drug: lopinavir/ritonavir
Drug: artemether/lumefantrine

First Posted Date: 2008-06-16

Last Posted Date: 2013-06-06

Lead Sponsor: Fran Aweeka

Target Recruit Count: 38

Registration Number: NCT00697892

Locations: 🇺🇸
San Francisco General Hospital, San Francisco, California, United States

Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics

Not Applicable

Completed

Conditions: HIV

Interventions: Drug: Efavirenz

First Posted Date: 2008-04-29

Last Posted Date: 2014-09-26

Lead Sponsor: Indiana University

Target Recruit Count: 73

Registration Number: NCT00668395

Locations: 🇺🇸
Indiana Clinical Research Center (ICRC), Indianapolis, Indiana, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States

Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy

Not Applicable

Completed

Conditions: HIV Infections
AIDS

Interventions: Drug: raltegravir
Drug: efavirenz

First Posted Date: 2008-04-21

Last Posted Date: 2017-05-30

Lead Sponsor: University of California, Davis

Target Recruit Count: 25

Registration Number: NCT00661960

Locations: 🇺🇸
CARES Clinic, Sacramento, California, United States
🇺🇸
UC Davis Medical Center, Sacramento, California, United States

ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Kivexa plus Sustiva
Drug: Atripla

First Posted Date: 2008-02-14

Last Posted Date: 2010-08-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 159

Registration Number: NCT00615810

Locations: 🇬🇧
Gilead Sciences, Granta Park, Cambridge, Abington, United Kingdom

Incidence and Severity of Neuropsychiatric Adverse Events of Efavirenz Given as a Stepped Dosage vs. the Usual Dosage

Phase 4

Completed

Conditions: HIV-1 Infection
HIV Infection

Interventions: Drug: Efavirenz

First Posted Date: 2007-11-12

Last Posted Date: 2009-01-15

Lead Sponsor: Sociedad Andaluza de Enfermedades Infecciosas

Target Recruit Count: 114

Registration Number: NCT00556634

Locations: 🇪🇸
Hospital Juan Ramon Jimenez, Huelva, Spain
🇪🇸
Hospital Universitario Puerta del Mar, Cadiz, Spain
🇪🇸
Hospital Torrecardenas, Almeria, Spain

and more 7 locations

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

Phase 1

Completed

Conditions: Hepatitis C
HIV Infections

Interventions: Drug: Efavirenz
Drug: Emtricitabine/Tenofovir disoproxil fumarate

First Posted Date: 2007-10-17

Last Posted Date: 2014-08-12

Lead Sponsor: University of Cincinnati

Target Recruit Count: 18

Registration Number: NCT00545558

Locations: 🇺🇸
General Clinical Research Center (GCRC), OH site, Cincinnati, Ohio, United States
🇺🇸
Virginia Commonwealth University, School of Medicine, Richmond, Virginia, United States

TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

Phase 3

Completed

Conditions: HIV Infections
HIV-1

Interventions: Drug: TMC278
Drug: efavirenz

First Posted Date: 2007-10-15

Last Posted Date: 2016-04-01

Lead Sponsor: Tibotec Pharmaceuticals, Ireland

Target Recruit Count: 680

Registration Number: NCT00543725

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

Phase 3

Completed

Conditions: HIV Infections
Human Immunodeficiency Virus Type 1
HIV-1

Interventions: Drug: TMC278
Drug: Efavirenz

First Posted Date: 2007-10-08

Last Posted Date: 2016-03-29

Lead Sponsor: Tibotec Pharmaceuticals, Ireland

Target Recruit Count: 694

Registration Number: NCT00540449

Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg

Phase 4

Terminated

Conditions: Tuberculosis
HIV Infections

Interventions: Drug: efavirenz

First Posted Date: 2007-09-21

Last Posted Date: 2015-11-10

Lead Sponsor: Oswaldo Cruz Foundation

Target Recruit Count: 130

Registration Number: NCT00533390

Locations: 🇧🇷
FIOCRUZ Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil
🇧🇷
Universidade Federal do Espirito Santo, Vitoria, Espirito Santo, Brazil

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy